| 生物活性 |
Isoastragaloside I is a natural compound found in Astragalus membranaceus that possesses oral activity and multiple biological activities such as anti-inflammatory and antioxidant effects; it inhibits Akt, NF-κB, MAPKs, and PI3K, enhances hepatic FXR activity, regulates the TGF-β/Smads signaling pathway, upregulates Nrf2 downstream antioxidant molecules, suppresses the expression of NO, TNF-α, iNOS, COX-2, IL-1β, and VCAM-1, and reduces intracellular ROS levels, while also alleviating blood-brain barrier disruption, restoring intestinal barrier function, increasing β-cell mass, improving glucose homeostasis, and elevating circulating adiponectin levels, and can therefore be used for research on neuroinflammation-related neurodegenerative diseases, cholestatic liver disease, and diabetes. |
体外研究 (In Vitro) |
Isoastragaloside I (ISO I) (5-100 μM; 24 h) 对 BV-2 小胶质细胞无细胞毒性作用。 Isoastragaloside I (25-100 μM; 2 h pre-treatment, followed by 20 h LPS stimulation) 可剂量依赖性地抑制 LPS 诱导的 BV-2 小胶质细胞分泌 NO 和 TNF-α。 Isoastragaloside I (100 μM; 2 h pre-treatment, followed by 20 h LPS stimulation) 可抑制 BV-2 小胶质细胞中 LPS 诱导的 iNOS 和 COX-2 蛋白表达,NF-κB、IκBα、p38、JNK 和 ERK1/2 的磷酸化。 Isoastragaloside I (100 μM; 2 h pre-treatment, followed by 20 h LPS stimulation) 可下调 BV-2 小胶质细胞中 LPS 诱导的 TNF-α、IL-1β 及 iNOS mRNA 的表达。 Isoastragaloside I (100 μM; 2 h pre-treatment, followed by 20 h LPS stimulation) 可抑制 BV-2 小胶质细胞中 LPS 诱导的 NF-κB 反式激活活性。阻断 LPS 诱导的 BV-2 小胶质细胞中磷酸化 NF-κB 的核转位。 Isoastragaloside I (100 μM; 2 h pre-treatment, followed by 5-30 min LPS stimulation) 可抑制 BV-2 小胶质细胞中 LPS 诱导的 PI3K 和 Akt 磷酸化。 Isoastragaloside I (ISOI) (25-100 μM; 2 h pre-incubation, 1-24 h co-treatment with LPS) 预处理可抑制 LPS 诱导的 bEnd.3 细胞 TEER 降低。 Isoastragaloside I (25-100 μM; 2 h pre-incubation, 24 h co-treatment with LPS) 预处理可减轻 LPS 诱导的 bEnd.3 细胞中 Na+F− 渗出,降低 ROS 累积,恢复紧密连接蛋白 (ZO-1、occludin、claudin-5) 的表达。 Isoastragaloside I (25-100 μM; 2 h pre-incubation, 24 h co-treatment with LPS) 预处理可降低 LPS 诱导的 JAWS II 单核细胞与 bEnd.3 细胞的黏附作用。 Isoastragaloside I 预处理可降低脂多糖 (LPS) 诱导的 bEnd.3 细胞中 IL-1β、TNF-α、VCAM-1 和 ICAM-1 的 mRNA 表达水平。 Isoastragaloside I (100 μM; 2 h pre-incubation, 24 h co-treatment with LPS) 预处理可抑制 LPS 诱导的 bEnd.3 细胞中 VCAM-1 蛋白表达,恢复 LPS 降低的 bEnd.3 细胞中 Nrf2、HO-1 和 NQO1 蛋白表达。 Isoastragaloside I (25-100 μM; 24 h) 可激活 HEK293T 细胞中 Nrf2 的反式激活作用。 Isoastragaloside I (100 μM; 2 h pre-incubation, 24 h co-treatment with LPS) 预处理可增强 LPS 处理后 bEnd.3 细胞中被抑制的 Nrf2 核转位。 Isoastragaloside I (100 μM; 2 h pre-incubation, 12 or 24 h co-treatment with LPS after Nrf2 siRNA transfection) 预处理恢复 LPS 刺激的 bEnd.3 细胞紧密连接蛋白表达和 VCAM-1 表达的能力依赖于 Nrf2 信号通路,因为沉默 Nrf2 会消除该效应。 Isoastragaloside I (10 μM) 可在体外抑制胰腺导管类器官生长,而低剂量则不会改变类器官细胞的增殖。
Cell Viability Assay
| Cell Line: |
BV-2 microglial cells |
| Concentration: |
25, 50, 100 μM |
| Incubation Time: |
24 h |
| Result: |
Did not alter the viability of BV-2 cells. |
Western Blot Analysis
| Cell Line: |
LPS-stimulated BV-2 microglial cells |
| Concentration: |
100 μM |
| Incubation Time: |
2 h pre-treatment, followed by 20 h LPS stimulation |
| Result: |
Reduced LPS-triggered iNOS and COX-2 protein expression, and suppressed the phosphorylation of NF-κB and IκBα. Mitigated LPS-induced activation of p38, JNK and ERK1/2. |
Real Time qPCR
| Cell Line: |
LPS-stimulated BV-2 microglial cells |
| Concentration: |
100 μM |
| Incubation Time: |
2 h pre-treatment, followed by 20 h LPS stimulation |
| Result: |
Significantly reduced LPS-induced mRNA expression of TNF-α, IL-1β, and iNOS. |
Western Blot Analysis
| Cell Line: |
LPS-stimulated BV-2 microglial cells |
| Concentration: |
100 μM |
| Incubation Time: |
2 h pre-treatment, followed by 5, 15, or 30 min LPS stimulation |
| Result: |
Significantly attenuated LPS-induced phosphorylation of PI3K and Akt across all time points tested. |
Western Blot Analysis
| Cell Line: |
mouse brain endothelial bEnd.3 cells |
| Concentration: |
100 μM |
| Incubation Time: |
2 h pre-incubation; 24 h co-treatment with LPS |
| Result: |
Rescued LPS-induced reductions of ZO-1, occludin, and claudin-5 protein expression, with significant restoration of occludin and claudin-5 levels, and visible restoration of ZO-1 membrane localization. Restrained LPS-induced elevation of VCAM-1 protein levels and restored LPS-mediated downregulation of Nrf2, HO-1 and NQO1 protein expression.
|
Immunofluorescence
| Cell Line: |
mouse brain endothelial bEnd.3 cells |
| Concentration: |
100 μM |
| Incubation Time: |
2 h pre-incubation; 24 h co-treatment with LPS |
| Result: |
Increased nuclear Nrf2 fluorescence intensity, indicating enhanced Nrf2 nuclear translocation. |
Western Blot Analysis
| Cell Line: |
mouse brain endothelial bEnd.3 cells |
| Concentration: |
100 μM |
| Incubation Time: |
2 h pre-incubation; 12 or 24 h co-treatment with LPS, after Nrf2 siRNA transfection |
| Result: |
No longer exerted a significant effect on ZO-1, occludin, or claudin-5 levels when Nrf2 was silenced.\nDid not reverse LPS-induced VCAM-1 expression elevation when Nrf2 was silenced. |
|
体内研究 (In Vivo) |
Isoastragaloside I (IAS I) (20-50 mg/kg;口服;每日;4 周) 可剂量依赖性地缓解 DDC 诱导的 C57BL/6J 小鼠胆汁淤积性肝病,在肝损伤、纤维化、炎症、胆汁酸代谢及肠屏障功能方面均有显著改善。 Isoastragaloside I (IAS-I) (0.5-5 mg/kg;静脉注射;第 0-21 天) 可使健康小鼠的小胰岛质量显著增加约 60%;缓解 1 型糖尿病小鼠和 2 型糖尿病小鼠的症状并增加小胰岛质量。
| Animal Model: |
C57BL/6J (male, 8 weeks old, 18-20 g, DDC diet-induced cholestatic liver disease) |
| Dosage: |
20 mg/kg; 50 mg/kg |
| Administration: |
p.o.; daily; 4 weeks |
| Result: |
Increased body weight dose-dependently compared to the DDC model group. Reduced liver weight and liver/body weight ratio significantly. Reduced intraluminal porphyrin embolism, inflammatory cell aggregation, and portal duct reaction via H&E staining. Reduced collagen deposition significantly via Sirius Red staining. Dose-dependently reduced levels of alanine aminotransferase, aspartate aminotransferase, total bilirubin, direct bilirubin, alkaline phosphatase, and total bile acid compared to the DDC model group. Reduced liver hydroxyproline content and Sirius Red-positive area significantly. Reduced positive areas and mRNA/protein expression of cholangiocyte biomarkers cytokeratin 19 and cytokeratin 7 significantly. Reduced positive area and mRNA/protein expression of α-smooth muscle actin significantly. Reduced mRNA expression of collagen type I alpha 1 chain, collagen type IV, and transforming growth factor-β1 significantly. Reduced protein expression of TGF-β1 and phosphorylated Smad2/3 (p-Smad2/3)/Smad2/3 significantly. Reduced positive area and mRNA expression of F4/80 significantly. Reduced mRNA expression of tumor necrosis factor-α and interleukin-1β significantly. Reduced protein expression of interleukin-6 and CD68 significantly. Reduced levels of arachidonic acid metabolites 5-hydroxyeicosatetraenoic acid, 15-HETE, 11(S)-HETE, prostaglandin E2, prostaglandin D2, 14(15)-DiHET, and 11(12)-DiHET significantly. Increased levels of ω-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid significantly. Increased fecal bile acid concentrations, including tau-BAs, gly-BAs, uncon-BAs, and total BAs significantly. Normalized serum and liver bile acid profiles, with significant reductions in total BAs, uncon-BAs, con-BAs, and tau-BAs compared to the DDC model group. Increased liver levels of taurocholic acid, taurohyocholic acid, taurodeoxycholic acid, and taurochenodeoxycholic acid significantly. Increased mRNA expression of hepatic farnesoid X receptor, small heterodimer partner, cholesterol 7α-hydroxylase, sodium taurocholate cotransport peptide, and bile-salt export pump significantly. Increased protein expression of FXR and Cyp7a1 significantly. Improved colonic mucosal structural integrity, reduced inflammatory cell infiltration, and restored goblet cell count. Increased positive area and mRNA expression of zonula occludens protein 1 significantly. Increased mRNA expression of Occludin and Muc2 significantly. Increased protein expression of Occludin significantly. |
| Animal Model: |
ICR and C57BL/6 (8-week-old, healthy) |
| Dosage: |
0.5 mg/kg; 5 mg/kg |
| Administration: |
i.v.; days 0, 3, 7, 10, 14, 17, 21 |
| Result: |
Induced a statistically significant ~60% increase in small islet mass compared to controls at 0.5 mg/kg. Showed a non-significant trend towards increased total β-cell proportion and total β-cell mass at both doses. |
| Animal Model: |
C57BL/6 (6-week-old, type 2 diabetes induced by 3 months high-fat diet + 3 consecutive daily i.p. 50 mg/kg streptozotocin, blood glucose >16.7 mM on two consecutive days) |
| Dosage: |
0.5 mg/kg; 5 mg/kg |
| Administration: |
i.v.; days 0, 3, 7, 10, 14, 17, 21 |
| Result: |
Alleviated hyperglycaemia at both doses without affecting body weight. Improved insulin resistance only at 0.5 mg/kg (~40% AUC reduction), but not at 5 mg/kg, and did not improve glucose responsiveness at either dose. Increased small islet mass at both doses, with a non-significant trend towards increased total β-cell mass. |
| Animal Model: |
ICR (8-week-old, type 1 diabetes induced by single i.p. 150 mg/kg Streptozotocin (MS-Q80520), blood glucose >16.7 mM on two consecutive days) |
| Dosage: |
0.5 mg/kg |
| Administration: |
i.v.; days 0, 3, 7, 10, 14, 17, 21 |
| Result: |
Reduced fasting blood glucose without affecting body weight or glucose responsiveness. Increased β-cell proportion and total β-cell mass in the pancreas, as well as β-cell proportion in both small and large islets. Found that proliferating β-cells accounted for only 0.009% of total pancreatic cells, indicating the increase in β-cell mass was not primarily mediated by β-cell proliferation. |
| Animal Model: |
SOX9-CreERT2; R26-LSL-tdTomato (type 1 diabetes induced by single i.p. 150 mg/kg streptozotocin, blood glucose >16.7 mM on two consecutive days; ductal cells labelled via 5 consecutive daily i.p. 75 mg/kg tamoxifen (MS-L29547) prior to diabetes induction) |
| Dosage: |
0.5 mg/kg |
| Administration: |
i.v.; days 0, 3, 7, 10, 14, 17, 21 |
| Result: |
Alleviated hyperglycaemia compared to controls. Showed co-localization of tdTomato+ duct-derived cells with Insulin+ β-cells in islets and small islets, and significantly increased the proportion of duct-derived Insulin+ cells to 3.1% of total tdTomato+ cells compared to controls. Resulted in proliferating β-cells almost exclusively arising from SOX9-derived cells. |
|